Pliant Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Pliant Therapeutics has a total shareholder equity of $313.3M and total debt of $9.9M, which brings its debt-to-equity ratio to 3.2%. Its total assets and total liabilities are $350.6M and $37.3M respectively.
Key information
3.2%
Debt to equity ratio
US$9.93m
Debt
| Interest coverage ratio | n/a |
| Cash | US$331.19m |
| Equity | US$313.34m |
| Total liabilities | US$37.27m |
| Total assets | US$350.61m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 9PT's short term assets ($340.3M) exceed its short term liabilities ($23.9M).
Long Term Liabilities: 9PT's short term assets ($340.3M) exceed its long term liabilities ($13.4M).
Debt to Equity History and Analysis
Debt Level: 9PT has more cash than its total debt.
Reducing Debt: 9PT's debt to equity ratio has increased from 0% to 3.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 9PT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 9PT has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 40.3% each year.